NeoPharm initiated by Merrill at buy

NeoPharm Inc. was initiated by Merrill Lynch analyst David Munno at a buy rating with a price target of $15 per share. The Lake Forest, Ill.-based biotech is developing oncology treatments for brain cancer, colorectal cancer, ovarian cancer, breast cancer and others. NeoPharm shares Thursday rose 48 cents, or 4.75%, to $10.58 on volume of 172,852 shares versus the three-month running average of 122,269.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.